

SCIENTIFIC PROGRAM

12:30-13:30 Registration, poster mounting

13:30-14:45 Oral presentations

Chairs: **Dimitra-Ioanna Lampropoulou, Evangelia Pantazaka**

- 13:30-13:45** **OP01** **Styliani A. Chasapi:** Urine Metabolomics for Early-Stage Diagnosis and Etiological Differentiation of Chronic Kidney Disease
- 13:45-14:00** **OP02** **Dimitra Triantafillidi:** Pharmacogenetic analysis of variants in IL-6 signaling and response to modern therapeutic approaches in Greek patients with atopic dermatitis
- 14:00-14:15** **OP03** **Andriana Plevriti:** The small GTPase RhoA regulates Soluble CD163 (sCD163) activity on endothelial cells
- 14:15-14:30** **OP04** **George Leondaritis:** Novel Peptide Modulators of PTEN: From Protein-Protein Interactions to Functional Regulation
- 14:30-14:45** **OP05** **Eugenia Yiannakopoulou:** Introduction to COST Action CA24125 CardioPharmaGENET: Exploration of the roads of involvement of the Hellenic Society of Basic and Clinical Pharmacology

14:45-15:05 Satellite Lecture I

15:05-17:00 Thematic Session I – Animal models in cancer pharmacology

Chairs: **Nikolaos Dietis, George Liapakis**

- 15:05-15:25** **Vassilis Zoumpourlis:** The Ideological Framework of the Genetic Basis of Cancer, Oncogene Cloning and Mice as Experimental Tools
- 15:25-15:45** **Konstantinos Dimas:** Paving the Way in Cancer Therapy: Advantages and Weaknesses of Preclinical Cancer Models in Mice
- 15:45-16:05** **Nikolas Dietis:** Use of Zebrafish Xenografts as a Cancer Model for Drug Discovery and Translational Pharmacology
- 16:05-16:25** **OP06** **Petros Karamanakis:** Disulfiram and Copper in the Treatment of Glioblastoma
- 16:25-16:45** **OP07** **Athanasios Pseftogas:** Investigation of the role of negative regulators of the NF-κB signaling pathway in carcinogenesis using animal models



16:45-17:00 Discussion

17:00-17:30 Coffee break

17:30-19:15 Cardiovascular Pharmacology

Chair: **Evangelos Manolopoulos**

17:30-18:00 **Tassos Lympelopoulos:** A blockbuster's little helper: PDE4 inhibition boosts efficacy of glucagon-like peptide-1 analogs in cardiomyocytes and adipocytes

18:00-18:30 **Evangelos Manolopoulos:** Poly-omic approaches in the investigation of atrial fibrillation and anticoagulant pharmacotherapy

18:30-19:15 **Stavros Konstantinides:** Anticoagulant and Fibrinolytic Treatment: What Further Progress Can We Expect in the Year 2026?

19:15-21:00 Opening Ceremony

Chairs: **Evangelia Papadimitriou, Antonis Goulas**

Greetings

Stavros Topouzis: Innovation in the pharmacological targeting of new drugs approved by EMA, FDA and MHRA in the last 3 years



DAY 2 | Saturday, May 16, 2026

09:00-10:00 Drugs for infections

Chair: **Nikos Tsopanoglou**

09:00-09:30 **Panagiotis Papatheodorou:** From Threats to Therapeutics: Targeting and Using Bacterial Toxins

09:30-09:50 **OP08 Konstantinos Ioannidis:** Vancomycin Pharmacokinetics and Adsorptive Clearance During CVVHDF with an Oxiris Membrane: Mechanistic and Clinical Insights

09:50-10:00 **Discussion**

10:00-11:30 Thematic Session II – Clinical trials

Chair: **Ioannis Ellul**

10:00-10:20 **Elena Linardou:** The Present and Future of Clinical Trials: Challenges and Opportunities - The transition to a new model of clinical research

10:20-10:40 **Grigoris Sivolapenko:** Clinical Research and the Use of Real-World Data

10:40-11:00 **Evita Kofini:** Decentralized Clinical Trials and Artificial Intelligence are changing the facts

11:00-11:15 **Aggeliki Stefanaki:** Clinical Trials in Greece today - through the eyes of patients

11:15-11:30 **Discussion**

11:30-12:00 Coffee break

12:00-13:30 Respiratory pharmacology

Chair: **Andreas Papapetropoulos**

12:00-12:45 **EPHAR lecture**

Clive Page: Phosphodiesterase inhibitors in lung diseases

12:45-13:05 **Alexios Matralis:** Development of a dual-action aerosol, as an autotaxin inhibitor and PPAR γ agonist, for Idiopathic Pulmonary Fibrosis. A medicinal chemistry approach with translational potential

13:05-13:30 **Argyrios Tzouvelekis:** New therapeutic targets in Pulmonary Fibrosis

13:30-14:00 Satellite Lecture II

14:00-16:00 Poster session – Light lunch



15:30-16:00 **General Assembly of HSBCP**

16:00-18:00 **Cardiovascular pharmacology and metabolism**

Chair: **Stavros Topouzis**

16:00-16:45 **Haaglim Cho:** Endothelial Insulin Resistance due to increased adrenomedullin signaling contributes to obesity-induced T2D

16:45-17:10 **Grigorios Tsigkas:** Clinical management of dyslipidemia in secondary prevention

17:10-17:30 **Evangelia Zvintzou:** Triglyceride-rich lipoproteins and their role in residual cardiovascular risk: The contribution of icosapent ethyl

17:30-18:00 **Antonia Katsouda:** Persulfidation-phosphorylation crosstalk regulates beige adipocyte formation

18:00-19:30 **Thematic Session III - Molecular approaches to precision medicine for mental illness**

Chairs: **Antonis Goulas, George Papazisis**

18:00-18:20 **Myrto Samara:** The clinical deadlock of trial and error and the need for molecular biomarkers

18:20-18:40 **Georgia Ragia:** Drug-microRNAs: new biomarkers of response in depression?

18:40-19:00 **Chara Denti:** Translating pharmacogenetics into clinical practice: thoughts and experiences

19:00-19:20 **Georgios Patrinos:** Results of the PREPARE study in Greece


19:20-19:30 **Discussion**

19:30-20:30 **Honorary event for Professor of Pharmacology Achilleas Gravanis**

Former Professor of Pharmacology at the University of Crete Medical School and CEO of ReNeuroCell Therapeutics

Presentation of the honoree by Professor Andreas Papapetropoulos, Laboratory of Pharmacology, Department of Pharmacy, NKUA

Speech by the honoree: **Developing new drugs in Greece: is it feasible?**



DAY 3 | Sunday, May 17, 2026

09:00-11:05 Neuropharmacology

Chair: **Eftihia Asproдини**

- 09:00-09:15 **OP09** **Pavlina Pavlidi:** GPER1 Activation as a Novel Rapid-Acting Antidepressant Target: Sex-Dependent Mechanisms and Therapeutic Potential
- 09:15-09:30 **OP10** **Grigoris Agrafiotis:** Taurine Confers Multi-Target Neuroprotection in Retinal Ischemia/Reperfusion Injury via Modulation of Inflammatory and Stress Response Pathways
- 09:30-09:45 **OP11** **Charalampos L. Kandilakis:** Psychedelic Compounds as Modulators of Brain Network Dynamics: Receptor Mechanisms and Therapeutic Implications
- 09:45-10:00 **OP12** **Fragkiski Fragkiskatou:** Study of Genetic Polymorphisms Associated with Thrombophilia as Possible Risk Factors for Alzheimer's Disease
- 10:00-10:15 **OP13** **Aikaterini Stravoravdi:** CREATE Ecosystem for CNS Clinical Trials: An AI-Enabled Multimodal Platform for Patient Stratification, Digital Endpoints and Longitudinal Treatment Response Monitoring
- 10:15-10:35 **OP14** **Eirini Kanata:** RNA editing highlights novel pharmacological targets in ALS
- 10:35-11:05 **Katerina Antoniou:** The regulatory role and therapeutic potential of cannabinoids

11:05-12:00 Cell Therapies – Regenerative Medicine

Chair: **Konstantinos Xanthopoulos**

- 11:05-11:35 **Stavros Taraviras:** Ependymal cell regeneration: How close are we to treating Hydrocephalus?
- 11:35-12:00 **Panagiotis Antoniou:** Therapeutic genome editing for hemoglobinopathies; the CRISPR 2.0 era

12:00-12:30 Coffee break

12:30-14:15 New approaches for pharmacological targeting

Chair: **Konstantinos Tamvakopoulos**

- 12:30-13:00 **Manolis Fousteris:** PROTACs: Design Principles and Therapeutic Potentials
- 13:00-13:30 **Ioannis Vizirianakis:** Towards the elucidation of the pharmacological potential of exosomes: challenges and perspectives for translational research and beyond
- 13:30-13:45 **OP15** **Sophia Antimisiaris:** Dual-functionalized synthetic nanoshuttles with therapeutic potential in stroke



13:45-14:00

OP16

Paraskevi Papakyriakopoulou: A Novel Noninvasive Intranasal Administration Technique of Biodegradable Polymeric Films for Targeted Nose-to-Brain Delivery in Mice

14:00-14:15

OP17

Aikaterini Maria Petrova: Metabolomics evaluation of MYC Degraders in Cancer cells

14:15-15:15

Thematic Session IV - Looking to the future: 3D Printing of Drugs in the Service of Personalized Pharmaceutical Treatment

Chair: **Evangelia Zvintzou**

14:15-14:30

Kyriakos Kypraios: 3D printing of drugs

14:30-14:45

Patroklos Vareltzis: Principles of Good Manufacturing Practice

14:45-15:00

Dimitris Anagnostopoulos: Challenges in market access

15:00-15:15

Discussion

15:15-16:00

Conference Closing – Awards Ceremony